Navigation Links
Valeant Pharmaceuticals Files Presentation for Cephalon Stockholders
Date:4/11/2011

MISSISSAUGA, Ontario, April 11, 2011 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today filed with the Securities and Exchange Commission a presentation in connection with its written consent solicitation to stockholders of Cephalon, Inc. (NASDAQ: CEPH) for removal of Cephalon's current Board of Directors and election of its seven nominees in their place.  

Valeant compares its $73.00 per share all-cash offer, which would deliver immediate and certain value to Cephalon stockholders, to the uncertainty of Cephalon's standalone plan, which relies on the successful commercialization of a risky pipeline portfolio.  Valeant reaffirms its position that it would be willing to increase its offer price modestly if Cephalon's Board of Directors would allow Valeant to conduct due diligence and the results of such due diligence support a higher offer.  However, given Cephalon's rejection of Valeant's offer and refusal to engage in discussions, completing a transaction may only be possible following the written consent solicitation with a new Board of Directors in place.

Valeant is concerned that Cephalon's stockholders are not receiving a balanced message from the current Cephalon Board of Directors regarding the company's status or Valeant's offer.

  • Cephalon's pipeline is risky and represents uncertain value.  Cephalon has not developed a major novel product through actual launch since the U.S. launch of Provigil in 1998, which had already been launched in France by another company in 1994.  All of Cephalon's other large drugs, including Actiq, Treanda, Nuvigil, Fentora and Amrix, were all either already marketed or based off of marketed products.  The current strategy of develop
    '/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Valeant Pharmaceuticals Files Preliminary Consent Solicitation Statement With the SEC
2. Promius Pharma and Valeant Form Collaboration to Market Cloderm® Cream in the United States
3. Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash
4. GSK and Valeant Receive European Authorisation for Trobalt (retigabine)
5. Valeant Pharmaceuticals Extends Contract with J. Michael Pearson as CEO and Appoints Him as Chairman of the Board
6. Valeant Pharmaceuticals Completes Acquisition of PharmaSwiss S.A.
7. Valeant Announces Pricing of Senior Notes
8. Valeant Launches Senior Notes Offering
9. Valeant Pharmaceuticals to Present at RBC Capital Markets 2011 Healthcare Conference
10. Valeant Pharmaceuticals to Announce 2010 Fourth Quarter and Full Year Results on February 24, 2011
11. Valeant Pharmaceuticals Announces License Of ACZONE® (dapsone) Gel 5% In Canada
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Celsion Corporation (the "Company") (NASDAQ: CLSN ... institutional investors to purchase an aggregate of approximately $15 ... registered direct offering, led by a dedicated health care ... agreements with these investors pursuant to which the Company ...
(Date:1/15/2014)... DUBLIN , January 15, 2014 Shire plc ... waived the Office of Fair Trading (OFT) approval condition to the ... Incorporated (NASDAQ: VPHM).   As a result of the ... Shire expects to complete the tender offer on January 24, 2014 ...
(Date:1/15/2014)... , January 15, 2014 BreedIT ... the exclusive worldwide distributor of highly sophisticated agro-breeding solutions ... January 7, 2014, the Company,s board of directors appointed ... as its new member of the board. ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... Bolder BioTechnology, Inc. today announced that it has ... (SBIR) grant totaling $600,000 from the National Institute of ... of Health (NIH).  The grant will be used to ... analog to accelerate platelet recovery and improve survival in ...
... Technologies Foster Better Informed Consumers, Greater Interest in Personal... -- PHILADELPHIA, Pennsylvania, August 18, 2010 ... ... lpUnit=,PRN,; --> ... var s = ,; var first_result; // Results are keyed by longUrl, so we need to ...
Cached Medicine Technology:Bolder BioTechnology Announces $600,000 Grant from NIH to Study Long-Acting IL-11 Analog in Treating Acute Radiation Syndrome 2Advanced Web-Based Medical Technologies Foster Better Informed Consumers, Greater Interest in Personal Health Care 2Advanced Web-Based Medical Technologies Foster Better Informed Consumers, Greater Interest in Personal Health Care 3Advanced Web-Based Medical Technologies Foster Better Informed Consumers, Greater Interest in Personal Health Care 4Advanced Web-Based Medical Technologies Foster Better Informed Consumers, Greater Interest in Personal Health Care 5Advanced Web-Based Medical Technologies Foster Better Informed Consumers, Greater Interest in Personal Health Care 6Advanced Web-Based Medical Technologies Foster Better Informed Consumers, Greater Interest in Personal Health Care 7Advanced Web-Based Medical Technologies Foster Better Informed Consumers, Greater Interest in Personal Health Care 8
(Date:4/17/2014)... the first genetic variant specifically associated with the ... around 10-15 per cent of all breast cancer ... breast cancer sub-type, called invasive lobular carcinoma, gives ... this particular kind of breast cancer, which can ... today (Thursday) in the journal PloS Genetics ...
(Date:4/17/2014)... April issue of Experimental Biology and Medicine ... Rex Gaskins and Paul Kenis in the Institute ... the University of Illinois Urbana-Champaign describe their recent ... underlie a variety of cell functions including energy ... crucial roles in regulating normal cellular behavior, redox ...
(Date:4/17/2014)... Jon McCullers, MD, was recently invited to submit ... Nature Reviews Microbiology , one of the world,s ... infectious disease specialist, and chair of the Department ... Science Center, analyzed the epidemiology and microbiology of ... as well as more recent 2009 novel H1N1 ...
(Date:4/17/2014)... It,s estimated that as many as 10 million older ... of loneliness and isolation. , However, new research ... retired older Americans for six years found that ... of depression by more than 30 percent. , "That,s ... State University professor of telecommunication, information studies and media ...
(Date:4/17/2014)... from Boston University School of Medicine (BUSM) have ... consumption in an experimental model. The findings, reported ... Alcohol Abuse , may lead to more effective ... is one of the leading causes of illness ... negative economic impact by limiting the productivity of ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Internet use can help ward off depression among elderly 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2
... damage to DNA, study says , , THURSDAY, Dec. ... at risk of DNA damage from prolonged exposure to ... 83 airline pilots to 50 university faculty members from ... participants were analyzed for DNA abnormalities, specifically the number ...
... teens is slowing, survey finds , , THURSDAY, Dec. 11 (HealthDay ... teens, the abuse of painkillers such as Vicodin and Oxycontin ... in the use of drugs such as marijuana has stalled ... Institute on Drug Abuse says in its report, Monitoring ...
... The American Academy of Orthopaedic Surgeons (AAOS) has ... of Osteoarthritis of the Knee". These guidelines were explicitly ... knee replacement surgery. While a wide range of treatment ... patients after discussions with their physicians. , ...
... Growth Equities, Ltd. initiates coverage of PolyMedix Inc. (OTC ... $9.00 price target. PolyMedix focuses on developing novel ... The Company,s leading clinical development programs include the ... , , Emerging Growth ...
... President & CEO , , ... a drug delivery technology company, today announced that George DeMott, chairman ... position as chairman, effective immediately. Mr. DeMott will continue to ... , , The board of directors ...
... serious risk of a long-term hospital stay, and ventilator-associated ... 15% of all people who are ventilated, is among ... a higher resistance to antibiotics, patients who rely on ... as 26,000 Americans do every year. , Thanks to ...
Cached Medicine News:Health News:Pilots May Face Greater Cancer Risk 2Health News:10% of U.S. High School Seniors Use Vicodin 2Health News:10% of U.S. High School Seniors Use Vicodin 3Health News:AAOS Issues New Clinical Practice Guideline for Osteoarthritis of the Knee 2Health News:AAOS Issues New Clinical Practice Guideline for Osteoarthritis of the Knee 3Health News:Emerging Growth Equities, Ltd. Initiates Coverage of PolyMedix Inc. With a Buy Rating and a $9.00 Price Target 2Health News:DelSite Chairman George DeMott Resigns 2Health News:DelSite Chairman George DeMott Resigns 3Health News:There's a life-saving medical device sitting on your sink 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: